News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Daiichi Sankyo Co Ltd. Buys 20 Percent Stake in Ranbaxy Laboratories
October 17, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Oct 17 (Reuters) - Japan's Daiichi Sankyo Co said on Friday it had completed the purchase of 20 percent in India's Ranbaxy Laboratories, part of its plan to obtain a majority holding in the generic drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
MORE ON THIS TOPIC
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
February 11, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
February 11, 2026
·
8 min read
·
Annalee Armstrong
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
February 10, 2026
·
1 min read
·
Tristan Manalac
